Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pembrolizumab + cyclophosphamide is a combination therapy used primarily in oncology clinical trials. Pembrolizumab is a humanized monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1 and PD-L2, thereby enhancing T-cell mediated immune responses against tumors[6]. Cyclophosphamide is an alkylating agent that interferes with DNA replication and suppresses the immune system, but at low (metronomic) doses can modulate the tumor microenvironment to enhance immunotherapy efficacy. This combination has been studied in advanced cancers such as melanoma and ovarian cancer, where it aims to improve anti-tumor activity by combining immune checkpoint inhibition with cytotoxic or immunomodulatory effects of chemotherapy[3][8].
- Brand names
- Keytruda
- Other names
- pembrolizumab + cyclophosphamide
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on pembrolizumab + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + cyclophosphamide.